Scholarlink

Background <p>We have evaluated in a single-center retrospective study early and mid-term outcomes of intermittent warm blood and St. Thomas cold crystalloid cardioplegia in patients referred for coronary artery bypass grafting (CABG) due to acute coronary syndromes (ACS). From January 2018 to December 2023, 336 consecutive patients underwent isolated on-pump CABG (unstable angina = 234, 69.6%; N-STE-myocardial infarction = 66, 19.6%; STE-myocardial infarction = 36, 10.7%). Myocardial protection was achieved using warm blood cardioplegia (WBC, <i>n</i> = 215, 64%) or cold crystalloid cardioplegia (CCC, <i>n</i> = 121, 36%). Primary endpoints of the study were the rate of operative mortality and low cardiac output syndrome, cardiac enzymes CK-MB, and troponin-I release in the postoperative period, i.e., at time 0 and 12 and 24&#xa0;h after CABG. Secondary endpoints were the assessment of postoperative ventricular systolic function and mid-term results.</p> Results <p>Baseline characteristics and preoperative variables including cardiac enzymes values were similar. Based on the different administration protocol, as compared with CCC group, in WBC group, required number of cardioplegia’s doses per patient was higher (2.6 ± 0.8 vs 2.1 ± 0.8; <i>P</i> &lt; 0.0001), despite lower number of distal coronary artery anastomoses (2.8 ± 0.7 vs 3.0 ± 0.8; <i>P</i> = 0.027) and shorter time of aortic cross-clamping (60 ± 21 vs 67 ± 21&#xa0;min; <i>P</i> = 0.006). Completeness of revascularization was similar (100% vs 98%). Postoperative low cardiac output syndrome (5.8% vs 4.6%), mortality rate (3.3% vs 1.4%), left-ventricular ejection fraction (0.52 ± 0.07 vs 0.53 ± 0.07), overall CK-MB and troponin-I enzymes release were similar for two cardioplegia groups (<i>P</i> = NS, for all measurements). Within the WBC group, troponin-I and CK-MB release at time 0, 12, and 24&#xa0;h were lower when cardioplegia was repeated within 18&#xa0;min in comparison with a longer time of administration (<i>P</i> &lt; 0.05, for both measurements). The rate of CK-MB/CK-total ratio &gt; 5% was significantly lower at 12 and 24&#xa0;h after CABG when WBC was repeated within 18&#xa0;min (<i>P</i> &lt; 0.05). Cross-clamp duration (65 ± 30 vs 64 ± 22&#xa0;min) did not significantly correlate with CK-MB/CK-total ratio &gt; 5% (<i>P</i> = 0.81) in comparison to lower ratios. Five-year survival was similar (97% ± 1.5% vs 96% ± 3.0%; <i>P</i> = 0.83).</p> Conclusions <p>WBC and CCC seem to guarantee equivalent and satisfactory outcomes. A better protection appears to be achieved when WBC was administered in 18-min re-dosing interval.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Warm blood versus St. Thomas cold crystalloid cardioplegia in patients affected by acute coronary syndromes undergoing coronary artery bypass surgery

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月19日

查看全文
  • Paolo Nardi,
  • Dario Buioni,
  • Claudia Altieri,
  • Francesco Bonavita,
  • Valentina Ajello,
  • Giulia Franceschini,
  • Simona Bonarrigo,
  • Mattia Scognamiglio,
  • Alessandro Cristian Salvati,
  • Carlo Bassano,
  • Claudio Cortese,
  • Augusto D’Onofrio,
  • Giovanni Ruvolo

摘要

Background

We have evaluated in a single-center retrospective study early and mid-term outcomes of intermittent warm blood and St. Thomas cold crystalloid cardioplegia in patients referred for coronary artery bypass grafting (CABG) due to acute coronary syndromes (ACS). From January 2018 to December 2023, 336 consecutive patients underwent isolated on-pump CABG (unstable angina = 234, 69.6%; N-STE-myocardial infarction = 66, 19.6%; STE-myocardial infarction = 36, 10.7%). Myocardial protection was achieved using warm blood cardioplegia (WBC, n = 215, 64%) or cold crystalloid cardioplegia (CCC, n = 121, 36%). Primary endpoints of the study were the rate of operative mortality and low cardiac output syndrome, cardiac enzymes CK-MB, and troponin-I release in the postoperative period, i.e., at time 0 and 12 and 24 h after CABG. Secondary endpoints were the assessment of postoperative ventricular systolic function and mid-term results.

Results

Baseline characteristics and preoperative variables including cardiac enzymes values were similar. Based on the different administration protocol, as compared with CCC group, in WBC group, required number of cardioplegia’s doses per patient was higher (2.6 ± 0.8 vs 2.1 ± 0.8; P < 0.0001), despite lower number of distal coronary artery anastomoses (2.8 ± 0.7 vs 3.0 ± 0.8; P = 0.027) and shorter time of aortic cross-clamping (60 ± 21 vs 67 ± 21 min; P = 0.006). Completeness of revascularization was similar (100% vs 98%). Postoperative low cardiac output syndrome (5.8% vs 4.6%), mortality rate (3.3% vs 1.4%), left-ventricular ejection fraction (0.52 ± 0.07 vs 0.53 ± 0.07), overall CK-MB and troponin-I enzymes release were similar for two cardioplegia groups (P = NS, for all measurements). Within the WBC group, troponin-I and CK-MB release at time 0, 12, and 24 h were lower when cardioplegia was repeated within 18 min in comparison with a longer time of administration (P < 0.05, for both measurements). The rate of CK-MB/CK-total ratio > 5% was significantly lower at 12 and 24 h after CABG when WBC was repeated within 18 min (P < 0.05). Cross-clamp duration (65 ± 30 vs 64 ± 22 min) did not significantly correlate with CK-MB/CK-total ratio > 5% (P = 0.81) in comparison to lower ratios. Five-year survival was similar (97% ± 1.5% vs 96% ± 3.0%; P = 0.83).

Conclusions

WBC and CCC seem to guarantee equivalent and satisfactory outcomes. A better protection appears to be achieved when WBC was administered in 18-min re-dosing interval.